Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 9/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20775350 | 0.94 | EGFR (0.51) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL15279141 | 0.88 | EGFR (0.62) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL4743562 | 0.86 | EGFR (0.52) | EGFRERBB2SRCGAK | |
| SCHEMBL2965914 | 0.83 | SRC (0.55) | EGFRERBB2SRC | |
| SCHEMBL28801565 | 0.83 | EGFR (0.53) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL28945823 | 0.81 | EGFR (0.51) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL31506322 | 0.80 | SRC (0.45) | EGFRERBB2MAP2K1SRC | |
| SCHEMBL13427130 | 0.79 | EGFR (0.53) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL4786042 | 0.79 | SRC (0.63) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL6185004 | 0.79 | EGFR (0.46) | EGFRERBB2MAP2K1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264427-A1 | 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors | IGF1R, IGFBP1, IGFBP2 | EGFR 192/4885ERBB2 83/4885MAP2K1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.